<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Marvel Biosciences Corp — News on 6ix</title>
<link>https://6ix.com/company/marvel-biosciences-corp</link>
<description>Latest news and press releases for Marvel Biosciences Corp on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 11:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/marvel-biosciences-corp" rel="self" type="application/rss+xml" />
<item>
<title>Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit</title>
<link>https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-to-participate-and-present-at-the-2nd-neuroscience-innovation-partnering-and-licensing-summit</link>
<guid isPermaLink="true">https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-to-participate-and-present-at-the-2nd-neuroscience-innovation-partnering-and-licensing-summit</guid>
<pubDate>Thu, 23 Apr 2026 11:30:00 GMT</pubDate>
<description>CALGARY, Alberta, April 23, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC:...</description>
</item>
<item>
<title>Marvel Biosciences Announces Closing of Convertible Debenture Offering</title>
<link>https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-announces-closing-of-convertible-debenture-offering</link>
<guid isPermaLink="true">https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-announces-closing-of-convertible-debenture-offering</guid>
<pubDate>Fri, 17 Apr 2026 20:30:00 GMT</pubDate>
<description>Calgary, Alberta--(Newsfile Corp. - April 17, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (" ...</description>
</item>
<item>
<title>Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders</title>
<link>https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-identifies-liquid-formulations-for-neurodevelopmental-disorders</link>
<guid isPermaLink="true">https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-identifies-liquid-formulations-for-neurodevelopmental-disorders</guid>
<pubDate>Thu, 16 Apr 2026 11:00:00 GMT</pubDate>
<description>CALGARY, Alberta, April 16, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC:...</description>
</item>
<item>
<title>Marvel Biosciences Announces an Amendment to the Conversion Price for Marvel's Proposed Convertible Debenture Offering</title>
<link>https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-announces-an-amendment-to-the-conversion-price-for-marvels-proposed-convertible-debenture-offering</link>
<guid isPermaLink="true">https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-announces-an-amendment-to-the-conversion-price-for-marvels-proposed-convertible-debenture-offering</guid>
<pubDate>Mon, 13 Apr 2026 21:31:00 GMT</pubDate>
<description>Calgary, Alberta--(Newsfile Corp. - April 13, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (" ...</description>
</item>
<item>
<title>Marvel Biosciences Announces Proposed Convertible Debenture Offering</title>
<link>https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-announces-proposed-convertible-debenture-offering</link>
<guid isPermaLink="true">https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-announces-proposed-convertible-debenture-offering</guid>
<pubDate>Wed, 08 Apr 2026 20:30:00 GMT</pubDate>
<description>Calgary, Alberta--(Newsfile Corp. - April 8, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (" M...</description>
</item>
<item>
<title>Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures</title>
<link>https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-secures-financial-and-strategic-investment-with-5-horizon-ventures</link>
<guid isPermaLink="true">https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-secures-financial-and-strategic-investment-with-5-horizon-ventures</guid>
<pubDate>Tue, 07 Apr 2026 11:30:00 GMT</pubDate>
<description>CALGARY, Alberta, April 07, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRV...</description>
</item>
<item>
<title>Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204</title>
<link>https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-secures-alberta-innovates-funding-to-support-the-phase-i-testing-of-mb-204</link>
<guid isPermaLink="true">https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-secures-alberta-innovates-funding-to-support-the-phase-i-testing-of-mb-204</guid>
<pubDate>Mon, 30 Mar 2026 11:30:00 GMT</pubDate>
<description>CALGARY, Alberta, March 30, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC:...</description>
</item>
<item>
<title>Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204</title>
<link>https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-selects-novotech-as-cro-for-its-phase-i-clinical-trial-of-mb-204</link>
<guid isPermaLink="true">https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-selects-novotech-as-cro-for-its-phase-i-clinical-trial-of-mb-204</guid>
<pubDate>Wed, 25 Mar 2026 11:30:00 GMT</pubDate>
<description>CALGARY, Alberta, March 25, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRV...</description>
</item>
<item>
<title>Marvel Biosciences Receives Notice of Allowance for US Patent Application Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204</title>
<link>https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-receives-notice-of-allowance-for-us-patent-application-covering-composition-of-matter-for-its-lead-therapeutic-candidate-mb-204</link>
<guid isPermaLink="true">https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-receives-notice-of-allowance-for-us-patent-application-covering-composition-of-matter-for-its-lead-therapeutic-candidate-mb-204</guid>
<pubDate>Wed, 18 Mar 2026 11:00:00 GMT</pubDate>
<description>Calgary, Alberta--(Newsfile Corp. - March 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTC...</description>
</item>
<item>
<title>Marvel Biosciences Sponsors Scientific Meeting on Purines</title>
<link>https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-sponsors-scientific-meeting-on-purines-4</link>
<guid isPermaLink="true">https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-sponsors-scientific-meeting-on-purines-4</guid>
<pubDate>Wed, 04 Mar 2026 12:00:00 GMT</pubDate>
<description>Calgary, Alberta--(Newsfile Corp. - March 4, 2026) - Marvel Biosciences Corp. &#xA0; (TSXV: MRVL...</description>
</item>
<item>
<title>Marvel Biosciences Secures Funding to Develop Child-Friendly Liquid Formulation for Neurodevelopmental Disorders</title>
<link>https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-secures-funding-to-develop-child-friendly-liquid-formulation-for-neurodevelopmental-disorders</link>
<guid isPermaLink="true">https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-secures-funding-to-develop-child-friendly-liquid-formulation-for-neurodevelopmental-disorders</guid>
<pubDate>Wed, 18 Feb 2026 13:00:00 GMT</pubDate>
<description>Calgary, Alberta--(Newsfile Corp. - February 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (...</description>
</item>
<item>
<title>Marvel Biosciences Receives Japanese Patent Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204</title>
<link>https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-receives-japanese-patent-213000721</link>
<guid isPermaLink="true">https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-receives-japanese-patent-213000721</guid>
<pubDate>Tue, 03 Feb 2026 21:30:00 GMT</pubDate>
<description>Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), a drug discovery company developing novel therapeutics for autism spectrum disorder and related neurological conditions, is pleased to announce that the Japan Patent Office has granted Japanese Patent No. 2022-554855, titled "Purine Compounds for Treating Disorders," covering composition.</description>
</item>
<item>
<title>Toronto Stock Exchange, Marvel Biosciences Corp., The View from the C-Suite</title>
<link>https://6ix.com/company/marvel-biosciences-corp/news/toronto-stock-exchange-marvel-biosciences-corp-the-view-from-the-c-suite</link>
<guid isPermaLink="true">https://6ix.com/company/marvel-biosciences-corp/news/toronto-stock-exchange-marvel-biosciences-corp-the-view-from-the-c-suite</guid>
<pubDate>Mon, 22 Dec 2025 19:07:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - December 22, 2025) - Rod Matheson, Chief Executive Officer, a...</description>
</item>
<item>
<title>Marvel Biosciences Announces Grant of Deferred Share Units</title>
<link>https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-announces-grant-deferred-221500456</link>
<guid isPermaLink="true">https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-announces-grant-deferred-221500456</guid>
<pubDate>Mon, 10 Nov 2025 22:15:00 GMT</pubDate>
<description>Calgary, Alberta--(Newsfile Corp. - November 10, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces the award of 35,697 deferred share units ("DSUs") to Marvel's three independent directors, in lieu of cash payment for directors' fees.The DSUs will all vest on October 31, 2026. Vested DSUs shall be settled upon the directors' separation from service from the Company and expire 365 days...</description>
</item>
<item>
<title>Marvel Biosciences Announces Acceleration of Warrant Expiry Date</title>
<link>https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-announces-acceleration-warrant-090000133</link>
<guid isPermaLink="true">https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-announces-acceleration-warrant-090000133</guid>
<pubDate>Fri, 03 Oct 2025 09:00:00 GMT</pubDate>
<description>Calgary, Alberta--(Newsfile Corp. - October 3, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is announcing that, further to the Company's press releases of May 16, 2024, June 21, 2024 and July 19, 2024, the Company is formally providing notice that it will be accelerating the expiry date of the warrants issued in relation to its non-brokered private placement unit offering (the "Offering"). The..</description>
</item>
<item>
<title>Marvel Biosciences Granted Chinese Patent for Lead Therapeutic Candidate MB-204</title>
<link>https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-granted-chinese-patent-210500858</link>
<guid isPermaLink="true">https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-granted-chinese-patent-210500858</guid>
<pubDate>Mon, 18 Aug 2025 21:05:00 GMT</pubDate>
<description>Calgary, Alberta--(Newsfile Corp. - August 18, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, today announced that the China National Intellectual Property Administration (CNIPA) has granted patent number ZL202180020893.4, titled "Purine Compounds for Treating Disorders". The</description>
</item>
<item>
<title>Marvel Biosciences Announces Closing of Private Placement</title>
<link>https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-announces-closing-private-220500181</link>
<guid isPermaLink="true">https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-announces-closing-private-220500181</guid>
<pubDate>Mon, 12 May 2025 22:05:00 GMT</pubDate>
<description>Calgary, Alberta--(Newsfile Corp. - May 12, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces that, further to its press releases of March 28, 2025 and May 2, 2025, it has closed its non-brokered private placement (the "Offering"). Pursuant to the Offering, the Company issued an aggregate of 8,150,000 units (the "Units") at a price of $0.125 per Unit for aggregate ...</description>
</item>
<item>
<title>Marvel Biosciences Announces Closing of Second Tranche of Private Placement</title>
<link>https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-announces-closing-second-110000765</link>
<guid isPermaLink="true">https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-announces-closing-second-110000765</guid>
<pubDate>Fri, 02 May 2025 11:00:00 GMT</pubDate>
<description>Calgary, Alberta--(Newsfile Corp. - May 2, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that, further to its press release of March 28, 2025 and subject to approval of the TSX Venture Exchange (the "TSXV"), it has closed the second tranche of its non-brokered private placement of up to 12,000,000 units (the "Units") at a price of $0.125 ...</description>
</item>
<item>
<title>Marvel Announces the Second of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide Following Cessation of Drug Treatment</title>
<link>https://6ix.com/company/marvel-biosciences-corp/news/marvel-announces-second-two-final-110000122</link>
<guid isPermaLink="true">https://6ix.com/company/marvel-biosciences-corp/news/marvel-announces-second-two-final-110000122</guid>
<pubDate>Wed, 30 Apr 2025 11:00:00 GMT</pubDate>
<description>Calgary, Alberta--(Newsfile Corp. - April 30, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to share part of the second final data set from its preclinical Rett syndrome study conducted in collaboration with Dr. Julie Le Merrer and Dr. Jerome Becker at the iBraiN Institute.The study evaluated MB-204, Marvel's lead compound (10 mg/kg oral once daily), in comparison ...</description>
</item>
<item>
<title>Marvel Biosciences to Give Oral Presentation at The Annual IRSF Rett Syndrome Scientific Meeting</title>
<link>https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-oral-presentation-annual-110000174</link>
<guid isPermaLink="true">https://6ix.com/company/marvel-biosciences-corp/news/marvel-biosciences-oral-presentation-annual-110000174</guid>
<pubDate>Wed, 16 Apr 2025 11:00:00 GMT</pubDate>
<description>Calgary, Alberta--(Newsfile Corp. - April 16, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (together "Marvel"), are pleased to announce their acceptance to give an oral presention at the International Rett Syndrome Foundation (IRSF) Scientific Meeting, taking place June 9-11th, 2025.Dr. Mark Williams, Chief Science Officer of Marvel, will present on behalf of the Company and its research collaborators, Dr. Julie Le Merre</description>
</item>
</channel>
</rss>